VNDA

8.13

3.30% 0.26

Dopo l'orario di chiusura: 8.15 0.02 +0.25%

Vanda Pharmaceuticals Inc (VNDA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$7.87

Aprire:

$7.93

Volume 24 ore:

2.09M

Relative Volume:

1.44

Capitalizzazione di mercato:

$480.46M

Reddito:

$192.64M

Utile/perdita netta:

$2.51M

Rapporto P/E:

155.15

EPS:

0.0524

Flusso di cassa netto:

$12.42M

1 W Prestazione:

+15.65%

1M Prestazione:

+50.83%

6M Prestazione:

+63.58%

1 anno Prestazione:

+69.73%

Intervallo 1D:

$7.88

$8.28

Intervallo di 1 settimana:

$7.85

$9.60

Portata 52W:

$3.8092

$9.60

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Nome

Vanda Pharmaceuticals Inc

Settore

Healthcare (1115)

Industria

Biotechnology (625)

Telefono

202-734-3400

Indirizzo

2200 PENNSYLVANIA AVE NW, WASHINGTON

Dipendente

368

Cinguettio

Prossima data di guadagno

2025-05-02

Ultimi documenti SEC

VNDA's Discussions on Twitter

Confronta VNDA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VNDA Vanda Pharmaceuticals Inc	8.13	465.09M	192.64M	2.51M	12.42M	0.0524
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-05	Iniziato	B. Riley Securities	Buy
2024-10-31	Iniziato	H.C. Wainwright	Buy
2024-07-11	Iniziato	Cantor Fitzgerald	Overweight
2022-02-25	Downgrade	Jefferies	Buy → Hold
2021-05-12	Iniziato	BofA Securities	Buy
2021-01-14	Downgrade	Citigroup	Buy → Neutral
2020-10-29	Aggiornamento	Citigroup	Neutral → Buy
2020-06-09	Downgrade	Citigroup	Buy → Neutral
2020-03-16	Downgrade	Oppenheimer	Perform → Underperform
2020-03-12	Aggiornamento	Citigroup	Neutral → Buy
2019-11-07	Downgrade	Citigroup	Buy → Neutral
2019-08-01	Aggiornamento	Citigroup	Neutral → Buy
2019-07-25	Downgrade	Stifel	Buy → Hold
2018-12-11	Downgrade	Oppenheimer	Outperform → Perform
2018-12-04	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2018-12-04	Reiterato	Jefferies	Buy
2018-11-08	Ripresa	Jefferies	Buy
2018-09-21	Ripresa	Oppenheimer	Outperform
2018-05-23	Iniziato	Citigroup	Buy
2018-01-19	Iniziato	Seaport Global Securities	Buy
2017-09-14	Reiterato	Piper Jaffray	Overweight
2017-06-27	Ripresa	Piper Jaffray	Overweight
2017-05-26	Iniziato	H.C. Wainwright	Buy
2017-04-12	Iniziato	Oppenheimer	Outperform
2016-11-09	Iniziato	Aegis Capital	Buy
2016-10-06	Ripresa	Jefferies	Buy

Mostra tutto

Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie

01:32 AM

FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside - Benzinga

01:32 AM

07:52 AM

HC Wainwright Analysts Raise Earnings Estimates for VNDA - MarketBeat

07:52 AM

Jan 05, 2026

FDA Grants Approval to Vanda Pharma’s Motion Sickness Medication, Boosting Growth Potential - Bitget

Jan 05, 2026

Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness - Yahoo Finance

Jan 05, 2026

VIX Spike: Can Vanda Pharmaceuticals Inc VM4 stock surprise markets with earningsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - moha.gov.vn

Jan 05, 2026

VNDA: HC Wainwright & Co. Raises Price Target to $22, Maintains Buy Rating | VNDA Stock News - GuruFocus

Jan 05, 2026

Gastric Motility Disorder Drugs Market is expected to reach US$ - openPR.com

Jan 05, 2026

Jan 04, 2026

Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN

Jan 04, 2026

Jan 03, 2026

Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to "Hold" at Wall Street Zen - MarketBeat

Jan 03, 2026

Jan 02, 2026

Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha

Jan 02, 2026

Jan 01, 2026

Vanda's tradipitant can significantly reduce nausea in those taking a GLP-1 - MSN

Jan 01, 2026

Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review - MSN

Jan 01, 2026

Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley - Yahoo Finance

Jan 01, 2026

Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus (NASDAQ:VNDA) - Seeking Alpha

Jan 01, 2026

After 40 Years, USFDA Approves Vanda Pharma's Motion Sickness Drug Nereus - Medical Dialogues

Jan 01, 2026

VNDA obtains FDA nod for motion sickness drug, stock gains - MSN

Jan 01, 2026

Vanda wins FDA approval for NEREUS motion sickness drug - MSN

Jan 01, 2026

Dec 31, 2025

Jefferies Initiates Vanda Pharmaceuticals(VNDA.US) With Hold Rating, Announces Target Price $7.5 - 富途牛牛

Dec 31, 2025

Vanda stock jumps with FDA approval of motion sickness drug - BioWorld MedTech

Dec 31, 2025

Vanda Pharmaceuticals hits 3-year high after FDA approves Nereus | Tap to know more | Inshorts - Inshorts

Dec 31, 2025

US FDA approves Vanda Pharmaceuticals' motion sickness drug - Reuters

Dec 31, 2025

D.C.-based Vanda gets FDA nod for motion-sickness treatment - The Business Journals

Dec 31, 2025

B. Riley Securities Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Raises Target Price to $14 - 富途牛牛

Dec 31, 2025

B. Riley Securities Raises Price Target for VNDA to $14.00 Maint - GuruFocus

Dec 31, 2025

Vanda Pharmaceuticals price target raised to $14 from $11 at B Riley - MSN

Dec 31, 2025